BeOne Medicines AG
beonemedicines.comWhat Do They Do?
Develops and sells cancer medicines for blood cancers and solid tumors through distributors and hospitals serving patients worldwide.
10-K for FY2025, filed Feb 26, 2026We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients…View ↗
Our hematology franchise is led by BRUKINSA, which is supported by a broad clinical program with over 7,900 patients enrolled in more than…View ↗
Our solid tumor franchise is led by our anti-PD-1 monoclonal antibody, TEVIMBRA, which is currently approved in the U.S., EU, China and…View ↗
In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and…View ↗
Who Are Their Customers?
In the U.S., specialty pharmacies and distributors buy products for resale; in Europe, sales go through distributors or directly to hospitals; in China, distributors resell medicines to hospitals and pharmacies.
10-K for FY2025, filed Feb 26, 2026In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and…View ↗
How Are They Changing?
-
May 15, 2026
FDA grants accelerated approval to BEQALZI for mantle cell lymphoma
The approval covers adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.
Sources
8-K, filed May 15, 2026
On May 13, 2026, BeOne Medicines Ltd. announced that BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug…View ↗
TEVIMBRA commercial rights The older report listed tislelizumab rights outside North America, Japan and the EU; the latest lists BeOne's commercial rights to TEVIMBRA as global.
Sonrotoclax approval
The older report described BRUKINSA, tislelizumab and pamiparib as approved internally developed medicines; the latest lists sonrotoclax as approved in China.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 26, 2026We currently have three approved medicines that were discovered and developed in our own labs, including BRUKINSA®, a small molecule…View ↗
PRODUCT MECHANISM OF ACTION REGULATORY STATUS BEONE COMMERCIAL RIGHTS PARTNER BRUKINSA® (zanubrutinib) BTK inhibitor Approved in 77…View ↗
Who Do They Compete With?
Competes with AbbVie, Janssen, AstraZeneca, Eli Lilly, Innocare, Merck, Bristol Myers Squibb, Roche, Merck KGaA, Regeneron, Sanofi, GSK, Junshi, Henlius, Ascentage Pharma, and Nurix Therapeutics
10-K for FY2025, filed Feb 26, 2026AbbVie & JanssenView ↗
Loading...
